Showing results (111-120 of 120) with videos related to
Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
International Journal of Cancer|February 11, 2020
End of an era for erythropoiesis-stimulating agents in oncologyMartin W Schoen, Shamia Hoque, Bartlett J Witherspoon, et al.Journal of Oncology Practice|May 16, 2017
Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced AnemiaVirginia Noxon, Kevin B Knopf, LeAnn B Norris, et al.The Lancet. Oncology|December 3, 2020
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse ReactionsCharles L Bennett, Martin W Schoen, Shamia Hoque, et al.Journal of Public Health Management and Practice : JPHMP|June 4, 2024
State Requirements for Non-Medical US Cannabis Retail PersonnelCassidy R LoParco, Yuxian Cui Msph, Darcey McCready Ms, et al.Plos One|June 26, 2020
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemiaShamia Hoque, Brian J Chen, Martin W Schoen, et al.Plos One|August 1, 2019
Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactionsCharles L Bennett, Benjamin Schooley, Matthew A Taylor, et al.The Lancet. Oncology|November 8, 2016
Generic oncology drugs: are they all safe?Y Tony Yang, Sumimasa Nagai, Brian K Chen, et al.The Oncologist|February 15, 2021
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse ReactionsCharles L Bennett, Sumimasa Nagai, Andrew C Bennett, et al.The Oncologist|March 8, 2019
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and CanadaBrian Chen, Sumimasa Nagai, James O Armitage, et al.Eclinicalmedicine|February 8, 2021
Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR)Charles L Bennett, Shamia Hoque, Nancy Olivieri, et al.Pageof 12